“But on top of that, it also opens up the door for access in Medicare, and with the decision that CMS announced back in April this year, we are confident that we will gain access also for OSA in Medicare.”

In context

“e some new data in the first part of 2026 since both the employers are making those decisions effective one-one in the new year to come. So I think we are very, very optimistic in that part of our business, but we're also continuing to make progress in terms of access for Medicaid. And just since we connected last time, we have gained six incremental states for Medicaid and most recently effective 10-1, we have California and Massachusetts. So big states are now covering more than 30 million lives, and we expect to continue to make progress in that space. And lastly, I would just emphasize the potential approval here of obstructive sleep apnea. The approval of obstructive sleep apnea will help us with employer opt-in because we know that outcome studies are critical to convince employers. But on top of that, it also opens up the door for access in Medicare, and with the decision that CMS announced back in April this year, we are confident that we will gain access also for OSA in Medicare. So I think we have many reasons to be excited about the outlook for 2025, driven by improved access across the commercial America space as well as the investments we have done, we believe to be direct. Joe Fletcher: Thanks, Patrik. And Mohit, even though you didn't ask about OUS access, and I don't allow multipart questions, maybe I'll see if Ilya wants to chime in and talk a little bit about OUS access progress to-date and what we see going forward. Ilya, do you want to -- would you like to chime in on that? Ilya Yuffa: Sure. Overall, we have seen significant progress on our launches OUS. We have both access for Type-2 diabetes where in some of the markets like U.K., Germany and Japan, and we're seeing some good progression of our share in those markets where we're already seeing leading”